Evidence map›Paper›PMID 35163939›Full record

ArticleMolecules (Basel, Switzerland)2022

Synthesis, Antimicrobial, Anti-Virulence and Anticancer Evaluation of New 5(4

Ahmad J Almalki, Tarek S Ibrahim, Ehab S Taher, Mamdouh F A Mohamed, Mahmoud Youns, Wael A H Hegazy, Amany M M Al-Mahmoudy

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Synthesis,Molecular diversity · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Disclosing New Insights on Pyrazolo[3,4-Journal of microbiology and biotechnology · 2025
    Article
  8. Article
  9. Anti-QS Strategies AgainstMicroorganisms · 2025
    Review
  10. Article
  11. Piceatannol: a renaissance in antibacterial innovation unveiling synergistic potency and virulence disruption against serious pathogens.International microbiology : the official journal of the Spanish Society for Microbiology · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Assessing the antibacterial potential of 6-gingerol: Combined experimental and computational approaches.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Ahmad J AlmalkiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-1333-980X
Tarek S IbrahimDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-3049-4617
Ehab S TaherDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.ORCID 0000-0002-1091-2885
Mamdouh F A MohamedDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt.ORCID 0000-0002-7046-1799
Mahmoud YounsDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt.ORCID 0000-0001-8754-9634
Wael A H HegazyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0001-5683-4803
Amany M M Al-MahmoudyDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
King Abdulaziz University · SAZagazig University · EGAl-Azhar University · EGHelwan University · EGSohag University · EG

Funding

The Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, Saudi Arabia RG-17-166-42
6 · The paper itself

Abstract

Since the synthesis of prontosil the first prodrug shares their chemical moiety, sulfonamides exhibit diverse modes of actions to serve as antimicrobials, diuretics, antidiabetics, and other clinical applications. This inspiring chemical nucleus has promoted several research groups to investigate the synthesis of new members exploring new clinical applications. In this study, a novel series of 5(4

Indexed as

Anti-Bacterial AgentsBiofilmsOxazolonePseudomonas aeruginosaQuorum SensingStaphylococcus aureusSulfonamidesVirulenceVirulence FactorsAnti-Bacterial AgentsOxazoloneSulfonamidesVirulence Factorsantibiofilmanticancerantimicrobialanti-virulenceoxazolonesulfonamide

Identifiers

PMID35163939
PMCPMC8838850
OpenAlexW4206839018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.